Pharma Pen Testing: Why FDA and IP Risk Need Different Scoping

Pharmaceutical security teams are managing two distinct risk problems simultaneously, and most pen test scoping frameworks are built for only one of them. FDA compliance risk requires demonstrating that validated systems and electronic records are protected in ways that satisfy regulatory expectations. IP protection risk requires ensuring that formulation data, synthesis routes and clinical research cannot be reached by competitors or nation-state actors. Scoping a pen test that addresses both requires a different starting point than standard enterprise security testing.

Why Standard Scoping Fails in Pharma

A standard enterprise pen test scope is built around asset criticality and network exposure. The most critical systems get tested, the most exposed networks get scanned, and the report documents what was found. That approach misses the two things that matter most in pharma: the regulatory status of the systems being tested and the classification of the data those systems protect.

Testing a manufacturing execution system with the same methodology you would use on a corporate ERP produces findings that are technically accurate but practically useless. The MES is a validated system. Any change to it, including a change made to remediate a pen test finding, may require revalidation. Understanding that constraint before the test starts is not a procedural detail. It shapes the entire engagement.

Scoping Around FDA Compliance

The FDA-relevant scope in a pharma pen test centers on systems subject to 21 CFR Part 11 and cGMP requirements. These include manufacturing execution systems, laboratory information management systems, electronic batch record applications and any other system that creates, modifies or stores regulated electronic records. The question for each system is not just whether it is in scope for testing, but how it can be tested without putting its validated state at risk.

The answer for most validated systems is a qualified test environment. A mirror of the production system, built to the same specification, that can be tested actively without any risk to the production environment or the audit trail integrity that regulators expect to see. Building that environment takes time and coordination with the validation team. It needs to be part of the project plan before the engagement starts, not a problem discovered during scoping.

Scoping Around IP Protection

The IP protection scope in a pharma pen test is not defined by regulatory status. It is defined by data value. Formulation data, synthesis routes, clinical trial results and regulatory filing strategies represent years of R&D investment. The systems that hold that data, and the access paths that reach it, are the primary targets for both criminal actors and nation-state threat groups that specifically target pharmaceutical IP.

The most important and most often overlooked part of IP protection scoping is third-party access. Contract research organizations, contract development and manufacturing organizations, and external research partners all require access to pharma environments that involves some contact with high-value IP. Those access paths are rarely tested with the same rigor as internal systems, and they are frequently the path of least resistance for an attacker.

Building a Scope That Covers Both

A pharma pen test scope that addresses both FDA compliance and IP protection is not twice the work of a standard scope. It is a single scope built from two different risk frameworks applied to the same environment. The starting point is a complete asset inventory that classifies each system by both regulatory status and data sensitivity. From that inventory, the scope document defines the testing approach for each category: active testing in qualified test environments for validated systems, standard methodology for non-validated systems, and specific attention to the access paths that reach high-value IP.

The rules of engagement need to reflect pharma-specific constraints that a generic pen test provider may not anticipate. No active testing on production validated systems without an approved test environment. No testing during batch manufacturing runs. Change control documentation for any activity that touches a validated system, even in a test environment. These constraints do not limit what the test can find. They ensure that what the test finds is actually actionable.